Please use the form to arrange this
You have plateaued on GLP-1 monotherapy
As of 2025, the shortage is resolved, but patients and prescribers may still see intermittent disruptions in supply
Attenuated effects of rivastigmine in induced cytokine storm in mice
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
If you are in San Mateo or Los Gatos and want a thoughtful, evidence informed program, our med spa locations and contact details make it easy to reach our team for next steps
